Researchers discovered new antibiotic molecules that target Mycobacterium tuberculosis and make it less pathogenic for humans in collaboration with research partners in Germany and France. Furthermore, some of the found compounds may enable the re-treatment of tuberculosis with existing treatments, including strains of the bacterium that have already established drug resistance. The findings were published in Cell Chemical Biology as 'Discovery of dual-active ethionamide boosters blocking the Mycobacterium tuberculosis ESX-1 secretion pathway'.
